Neuromuscular Disorders News Archive
Investigators conducted a meta-analyses to determine whether injectable IFN-β and glatiramer acetate both decrease the annualized relapse rate and slow disease progression in patients with RRMS.
From 2005 to 2014, trends in palliative care use increased substantially among multiple sclerosis inpatients.
Prevalence of Pediatric Multiple Sclerosis Exceptionally High in Ontario, Canada Compared With Global Numbers
Researchers provide a practical, valid method to estimate the incidence and prevalence of MS in the pediatric population.
Specific locations of cerebral multiple sclerosis lesions appear to be associated with bowel incontinence.
Alkermes has submitted a New Drug Application to the FDA for a novel oral fumarate in development to treat relapsing forms of multiple sclerosis.
Rosalind C. Kalb, PhD, a clinical psychologist, offers her insights on how clinicians can address patient concerns about reproductive issues and MS.
Children with MS were more likely to receive a newer DMT prior to turning 18 years old compared with patients with CIS.
A new warning has been added to the multiple sclerosis drug Lemtrada (alemtuzumab) after rare reports of patients suffering strokes and tears in the lining of the arteries in the head and neck.
Rates of multiple sclerosis relapse decrease during pregnancy but increase postpartum.
The rate and frequency of relapse vary for patients with multiple sclerosis, and many report not visiting a health care provider during relapse.
From September 2010 to February 2018, the FDA has identified 35 cases of severe increased disability accompanied by the presence of new lesions on MRI that occurred 2 to 24 weeks after stopping treatment with fingolimod.
According to a Phase 3b open-label study, Ocrevus may interfere with the effectiveness of non-live vaccines.
Pediatric MS is predominantly inflammatory in nature, with a presentation that is similar to a number of other conditions.
A nationwide epidemiologic study in France examined a correlation between Guillain-Barré syndrome and recent bone or digestive organ surgery.
Nusinersen, an antisense oligonucleotide that increases functional SMN protein production from SMN2, was clinically effective for improving motor function.
Having a higher burden of comorbidities is associated with greater disability progression and lower QoL, as well as increased healthcare utilization and mortality.
Investigators sought to determine relapse rates of multiple sclerosis decrease prior to pregnancy, during pregnancy, and postpartum.
Tiglutik is supplied as a thickened riluzole liquid that is intended to ease administration for patients with dysphagia.
Investigators propose that myelocortical multiple sclerosis may be a subtype of multiple sclerosis.
Cannabinoids may be mildly effective at treating spasticity, pain, and bladder dysfunction in adults with multiple sclerosis.
Fingolimod shows superior efficacy to interferon beta-1a in pediatric multiple sclerosis: the PARADIGMS trial
Among pediatric patients with relapsing multiple sclerosis, fingolimod was associated with a lower annualized rate of relapse and lower incidence of new lesions identified on T2-weighted magnetic resonance imaging (MRI) compared to interferon beta-1a.
Investigators examine the role of physical activity and exercise in the modification of vascular comorbidities and risk factors in individuals with multiple sclerosis.
All participants were smokers or had either diabetes, cancer, depression, cardiovascular, respiratory, thyroid, or gastrointestinal disease and were receiving a DMT.
Natural history data from a subset of patients from the British Columbia MS database between 1980 to 1996 were used to create a continuous Markov model to model the projected course of disease in untreated people with RMS.
Compared with Copaxone injection, treatment with oral Gilenya significantly reduced the annualized relapse rate in patients with relapsing remitting multiple sclerosis.
Researchers categorized samples into quintiles based on 25(OH)D3 concentrations in healthy controls.
Patients with progressive MS or secondary progressive MS who were receiving care at a single institution in France were prescribed 300 mg/day MD1003.
In patients with relapse-remitting multiple sclerosis, the initiation of oral disease-modifying therapies is associated with a lower relapse risk as well as a lower risk for disability progression.
Disability progression is slower among patients with pediatric-onset multiple sclerosis.
Patients with MS also have a higher risk for serious hospitalized-related infections compared with hospitalized patients without MS.
Investigators examine the effect of disease-modifying therapy on the rate of brain atrophy in patients with multiple sclerosis.
Study investigators assessed the changes in the Expanded Disability Status Scale and MS Severity Score after up to 7 courses of alemtuzumab.
The phase 3 PARADIGMS trial involving 215 pediatric patients demonstrated superior efficacy for fingolimod over interferon beta-1a.
Patients were divided into 3 groups: patients not treated in the 3 months before pregnancy, patients treated in the 3 months before pregnancy, and patients treated during pregnancy.
Researchers pooled long-term data on the safety of cladribine tablets monotherapy that extended 3 or more years beyond the data included in the last clinical study.
Participants showed a significant decrease in annual relapse rate and a significant improvement in both patient-reported disability scores and information processing scores.
Treatments were evaluated for either 1 year (SUNBEAM) or 2 years (RADIANCE).
Surveys were given out to individuals in the Australian Multiple Sclerosis Longitudinal Study between August and December 2016.
Investigators examined factors associated with mobility and walking restrictions in participants with multiple sclerosis.
Researchers analyze the dietary habits of 260 patients in the early stages of multiple sclerosis from baseline to 5 years after initial onset of symptoms.
Patients with multiple sclerosis who initiated ocrelizumab therapy earlier and continued long-term treatment sustained lower annualized relapse rates.
Reserachers evaluated data from the CLARITY study to test the efficacy of cladribine tablets on frequency and severity of relapses for patients with multiple sclerosis.
Evidence suggests a possible role for inflammation in the association between MS and myocardial infarction risk.
Extended interval dosing of natalizumab may also be associated with reduced risk for progressive multifocal leukoencephalopathy.
The ESTEEM study included 3075 patients who were newly prescribed dimethyl fumarate to manage relapsing-remitting multiple sclerosis.
Early initiation of dimethyl fumarate and fingolimod may be associated with improved relapse control in multiple sclerosis relative to late therapy initiation.
Multiple sclerosis disease activity was less likely to decrease among tobacco users.
Previous studies have shown that excess adiposity is a strong risk factor for metabolic comorbidities and has been linked to poorer outcomes in people with neurologic diseases.
Higher depressive symptoms in patients with multiple sclerosis was associated with lower employment and processing speed.
Standard pen needles have an outer cover and removable inner needle cover, while safety pen needles have an outer cover and a fixed inner needle shield that is not removed before an injection.
Future studies on VR training for MS should include large randomized controlled trials using clear protocols and comparable between-group tasks.
Older individuals with multiple sclerosis report less severe depressive symptoms and better physical quality of life, compared to younger patients.
Patients with multiple sclerosis-related chronic pain were found to have spectral abnormalities within the dynamic pain connectome regions.
The primary outcome measure of the study was the frequency of any adverse psychiatric effect observed during treatment with one of these agents.
Investigators examined whether serum leptin and adiponectin could be potential biomarkers of disease activity in multiple sclerosis.
Brain iron at quantitative magnetic resonance imaging is associated with disability in multiple sclerosis.
The 2018 AANEM Annual Meeting is taking place at the Gaylord National Resort & Convention Center in Washington, DC.
Among pediatric patients with relapsing multiple sclerosis, fingolimod is associated with a lower rate of relapse but a higher rate of serious adverse events.
In patients with progressive multiple sclerosis, slower progression of brain atrophy was seen with ibudilast versus placebo.
Following adjustment for MS disease course, the genome-wide analysis identified an association between chromosome 1q32.2 and IFN-β-induced liver injury.
Although regarded as a miracle drug to some, nusinersen comes with some troublesome strings attached.
DMD is predominately caused by out-of-frame deletions in the dystrophin gene, which results in absent or defective dystrophin protein, leading to progressive and irreversible muscle function loss.
Investigators assess the diagnostic value of 2 CSF biomarkers to distinguish pediatric acquired demyelinating syndromes from non-acquired demyelinating syndromes.
Investigators aim to facilitate early recognition and consideration for patients with Duchenne muscular dystrophy and internalizing psychiatric symptoms.
The NDA resubmission is in response to the FDA's Complete Response Letter issued in 2011 which requested an improved understanding of the safety risks and overall benefit-risk profile.
The combination of genetics and exposure to organic solvents in paints and varnishes increases the risk of multiple sclerosis.
Brain volume loss has nonlinear dynamics and limited reproducibility as a marker of therapeutic response in multiple sclerosis.
ICU-acquired weakness syndromes manifest themselves in a range of ways among patients — as a spectrum of disease rather than in specific form.
SGT-001 is a novel adeno-associated viral vector mediated gene transfer that could potentially address the underlying genetic cause of DMD, mutations in the dystrophin gene.
A majority of the respondents in both groups identified reduced disability progression as a priority.
A new immunotherapy appears to be well tolerated and possibly of benefit in patients with amyotrophic lateral sclerosis.
A combination of dalfampridine extended-release and physical therapy (PT) has shown efficacy for improving gait in people with multiple sclerosis
Differing formulations and ratios of the subjects' medical cannabis regimens have been accounted for, though further information about ratios of CBD and TCH are subject to change due to continued ongoing research.
Pain in patients with multiple sclerosis may affect their daily functioning regardless of disease severity.
Investigators assessed the effect of disease-modifying treatments on pain in patients with relapsing-remitting multiple sclerosis.
The MS and monophasic ADS groups were compared using quantified melanin measurements via the DSM II Colorimeter; self-reported skin tones of fair, medium, olive, or dark; a self-reported race; and skin tone, which was self-reported using 10 numerical panels of color.
The protocol authors propose a more objective method of managing medication adherence through a profile performed by an occupational therapist.
Due to the increased risk for urinary tract infections (UTIs) in people with MS and similar CNS demyelinating diseases, as well as the tendency of UTIs to trigger more MS flares, the affected population are subject to a large number of unneeded antibiotic prescriptions and asymptomatic bacteriuria treatments.
The study researchers examined data from the US database of the IMS Health Real World Data Adjudicated Claims between 2011 and 2015.
Immunotherapy in multiple sclerosis may increase the risk for conversion from latent to active tuberculosis infection.
This study analyzed results from SUNBEAM (ClinicalTrials.gov Identifier: NCT02294058) and RADIANCE (ClinicalTrials.gov Identifier: NCT01628393), 2 double-blind, randomized, phase 3 trials.
Cognitive impairment is common in patients with multiple sclerosis (MS) and considerably impacts quality of life.
Alemtuzumab is associated with reduced magnetic resonance imaging disease activity and the slowing of brain volume loss over 7 years in patients with relapsing-remitting multiple sclerosis.
Brain volume loss was smaller for all groups after treatment with fingolimod.
TG1101-RMS201 was a multicenter, placebo-controlled, phase 2, 52-week study designed to evaluate the optimal infusion and safety of ublituximab for relapsing multiple sclerosis.
Analysis of yearly lymphocyte counts showed a declining occurrence of all grades of lymphopenia over time, and by year 9, subjects exhibited no cases of lymphopenia.
The multiple-logistic regression analyses determined that the most consistent predictors for negative clinical outcomes in months 12 to 48 were relapses during months 0 to 12 and EDSS scores at baseline and months 0 to 12.
This retrospective cohort study sought to assess the outcomes for individuals with multiple sclerosis who transitioned from natalizumab to dimethyl fumarate.
The VELOCE trial (ClinicalTrials.gov Identifier: NCT02545868) was an open-label, randomized, phase 3b study designed to assess whether ocrelizumab could raise the humoral responses to vaccines in individuals with relapsing multiple sclerosis.
Investigators explored the efficacy and safety of alemtuzumab in patients initially assigned to alemtuzumab in a previous trial followed by alemtuzumab treatment over a 2-year period in a core study plus an additional 4-year period in an extension trial.
Although the study demonstrated a lower relapse rate among patients with MS who supplemented their diet with vitamin D, the analysis did not reach statistical significance.
A prospective, blinded, randomized trial comparing once-weekly and twice-weekly IM IFNβ-1a may be indicated.
Patients with higher rates of depression and fatigue were significantly more likely to have lower MMAS-8 adherence scores.
The investigators examined the association between obesity and the age of first symptom(s), number of impaired functional domains, and early relapse activity in patients with MS.
Various clinical symptoms precede the diagnosis of multiple sclerosis by several years.
High-dose intravenous immunoglobulin therapy was administered to all patients and may have contributed to neutralization of eculizumab.
The FDA's decision was based on data from the Phase 3 PARADIGMS study (N=215) which evaluated the safety and efficacy of oral fingolimod vs interferon beta-1a injection in pediatric patients aged 10 to <18 years with relapsing MS.
ACE-083 is currently being studied in a Phase 2 trial for FSHD and another for Charcot-Marie-Tooth (CMT) disease.
Investigators designed a parallel-group, 2-arm, randomized controlled trial to evaluate ELEVIDA, an online fatigue management program based on cognitive behavioral therapy and other therapy-based strategies.
Previous studies have shown that delayed-release DMF is safe and effective in treating RRMS in adult patients. The goal of this study was to extend these analyses to evaluate DMF in pediatric patients with RRMS.
Neurology Advisor Articles
- Survival in Parkinson Disease Dependent on Parkinsonian Type, Characteristics
- Case Study Report: Herbal Supplement Kratom Associated With Neonatal Abstinence Syndrome
- Mobile Health Apps for Headache: An Ongoing Search for Clinical Relevancy
- CBD Superior to Placebo, Similar to AEDs for Managing Epilepsy Syndromes
- Young Fresh Frozen Plasma Infusion Safe, Feasible in Alzheimer Disease
- Alemtuzumab Linked to Clinical and MRI Disease Remission in Multiple Sclerosis
- Very Early Mobilization After Stroke Does Not Improve Survival Over Usual Care
- Cognitive Decline Worsens With Memantine, ChEIs in Patients With Alzheimer's
- Cervical Dysfunction Needs Clarification to Identify Link With Headache
- Levodopa Inhalation Powder Approved for Parkinson Disease
- Can Early Initiation of Direct Oral Anticoagulants Prevent Recurrent AFib-Related Stroke?
- Hydrocephalus May Be a Complication of Congenial Zika Syndrome
- Higher CSF NfL Protein Levels Linked to Risk for Mild Cognitive Impairment
- Addressing Cognitive Impairment in Pediatric MS: Expert Q&A
- How the Government Shutdown Affects FDA Activities